Heart failure (HF), a common complication of myocardial infarction (MI), occurs in 14%-36% of hospitalized patients. Patients with HF can present with a wide spectrum of clinical severity, ranging ...

Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through ...

The draft NICE quality standard for secondary prevention following myocardial infarction is now available for consultation. The consultation period will end at 5pm on Wednesday 8 April 2015. The ...

In an interview with HT Lifestyle, Dr Anup Taksande, Consultant Interventional Cardiologist at Wockhardt Hospitals in Mumbai's Mira Road, shared, “The primary cause of myocardial infarction is ...

Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect Zheng Zhou, Elham Rahme, Michal Abrahamowicz, Jack V. Tu, Mark J.

Objectives: The objectives of this drug utilization review programwere (1) to increase β-blocker prescribing to fee-for-servicepost-acute myocardial infarction (AMI) Medicaid patients; (2) ...

The largest analysis aimed at more accurately predicting the risk of sudden cardiac death after myocardial infarction is presented in late breaking results from the PROFID consortium at ESC Congress ...

When Asian dust clouds blow in to Japan's Kumamoto Prefecture, hospitals in the region handle a surge of acute myocardial infarctions (AMI) in the following 24 hours, and now a new prediction tool ...

The first clinical trial to challenge the routine implantation of a defibrillator in myocardial infarction survivors with heart failure has enrolled its first patient. The PROFID EHRA trial is part of ...